DE69716255T2 - Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln - Google Patents

Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln

Info

Publication number
DE69716255T2
DE69716255T2 DE69716255T DE69716255T DE69716255T2 DE 69716255 T2 DE69716255 T2 DE 69716255T2 DE 69716255 T DE69716255 T DE 69716255T DE 69716255 T DE69716255 T DE 69716255T DE 69716255 T2 DE69716255 T2 DE 69716255T2
Authority
DE
Germany
Prior art keywords
compound
middle ear
subject
use according
eustachian tube
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69716255T
Other languages
German (de)
English (en)
Other versions
DE69716255D1 (de
Inventor
J. Drutz
M. Jacobus
L. Rideout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inspire Pharmaceuticals Inc
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69716255D1 publication Critical patent/DE69716255D1/de
Publication of DE69716255T2 publication Critical patent/DE69716255T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Processing Of Solid Wastes (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE69716255T 1996-02-21 1997-02-14 Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln Expired - Fee Related DE69716255T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/604,463 US6423694B1 (en) 1996-02-21 1996-02-21 Method of treating otitis media with uridine triphosphates and related compounds
PCT/US1997/002299 WO1997029756A1 (en) 1996-02-21 1997-02-14 Method of treating otitis media with uridine triphosphates and related compounds

Publications (2)

Publication Number Publication Date
DE69716255D1 DE69716255D1 (de) 2002-11-14
DE69716255T2 true DE69716255T2 (de) 2003-07-03

Family

ID=24419702

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69716255T Expired - Fee Related DE69716255T2 (de) 1996-02-21 1997-02-14 Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln

Country Status (11)

Country Link
US (1) US6423694B1 (cg-RX-API-DMAC7.html)
EP (1) EP0897301B1 (cg-RX-API-DMAC7.html)
JP (1) JP2000505447A (cg-RX-API-DMAC7.html)
KR (1) KR19990082562A (cg-RX-API-DMAC7.html)
CN (1) CN1211186A (cg-RX-API-DMAC7.html)
AT (1) ATE225663T1 (cg-RX-API-DMAC7.html)
AU (1) AU730888B2 (cg-RX-API-DMAC7.html)
CA (1) CA2246581A1 (cg-RX-API-DMAC7.html)
DE (1) DE69716255T2 (cg-RX-API-DMAC7.html)
NZ (1) NZ331446A (cg-RX-API-DMAC7.html)
WO (1) WO1997029756A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2250188C (en) * 1996-03-27 2008-12-09 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US6420347B1 (en) 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
DE19718826A1 (de) * 1997-05-05 1998-11-12 Marion S Dr Eckmiller Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
AU747196B2 (en) * 1997-07-25 2002-05-09 Merck Sharp & Dohme Corp. Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
CN100354296C (zh) * 1998-10-02 2007-12-12 雅玛山酱油株式会社 二尿苷四磷酸或其盐的晶体和其制备方法、以及制备该化合物的方法
KR100475008B1 (ko) * 1998-10-02 2005-03-08 야마사 쇼유 가부시키가이샤 디우리딘 테트라포스페이트 또는 그의 염의 결정 및 그의제조법, 그리고 그 화합물의 제조법
US6645532B1 (en) * 1999-01-19 2003-11-11 Matthew Lutin Compositions and method for relieving discomfort in the ears
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
JP2005508297A (ja) 2001-06-25 2005-03-31 インスパイアー ファーマシューティカルズ，インコーポレイティド Ｐ２ｙプリン受容体作用物質による関節潤滑
KR20050043761A (ko) 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
MXPA05004121A (es) * 2002-10-18 2006-02-17 Molichem Medicines Inc Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
WO2005115432A2 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
AU2007221150B2 (en) 2006-02-27 2012-09-20 Ahm Technologies, Inc. Eustachian tube device and method
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7976873B2 (en) * 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US8088095B2 (en) * 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
US20090197956A1 (en) * 2008-02-04 2009-08-06 Arbor Pharmaceuticals, Inc. Treatment of acute otitis media with xylitol and n-acetylcysteine
JP2011524367A (ja) 2008-06-12 2011-09-01 メドトロニック・ゾーメド・インコーポレーテッド 慢性の創傷を治療するための方法
EP2346324A4 (en) * 2008-10-06 2012-10-10 Microbial Defense Systems Llc ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING
CA2835211C (en) 2011-05-10 2019-09-24 Next Science, Llc Antimicrobial solid and methods of making and using same
HU227743B1 (en) * 2011-07-22 2012-02-28 Debreceni Egyetem Eardrop composition and process for producing this

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260073A (en) * 1990-05-21 1993-11-09 Norwich Eaton Pharmaceuticals, Inc. Use of phenylpropanolamine as a mucus secretogogue in the upper airways
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
FR2684299B1 (fr) * 1991-12-02 1995-03-24 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique et de l'amiloride.
FR2677250B1 (fr) * 1991-06-05 1995-01-20 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds

Also Published As

Publication number Publication date
CA2246581A1 (en) 1997-08-21
KR19990082562A (ko) 1999-11-25
WO1997029756A1 (en) 1997-08-21
AU2272497A (en) 1997-09-02
US6423694B1 (en) 2002-07-23
EP0897301B1 (en) 2002-10-09
AU730888B2 (en) 2001-03-15
CN1211186A (zh) 1999-03-17
DE69716255D1 (de) 2002-11-14
ATE225663T1 (de) 2002-10-15
JP2000505447A (ja) 2000-05-09
EP0897301A1 (en) 1999-02-24
NZ331446A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
DE69716255T2 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
US5958897A (en) Method of treating sinusitis with uridine triphosphates and related compounds
DE69736468T2 (de) Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
DE69822482T2 (de) Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
EP1087777B1 (en) Therapeutic dinucleotide and derivatives
DE69632743T2 (de) Verfahren zur regulierung des vagaltonus
DE69725160T2 (de) Verwendung von uridin-triphosphat verwandte verbidungen zur prävention und behandlung von pneumonie in immobilisieren patienten
DE69636734T2 (de) Nucleoside mit anti-hepatitis b virus wirksamkeit
WO1997035591A9 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US6420347B1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
DE3873207T2 (de) Antivirale therapie gegen hepatitis b mit 2',3'-didesoxynucleosiden.
US6673779B2 (en) Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
KR100549904B1 (ko) 우리딘트리포스페이트및관련화합물을함유하는섬모운동장해치료용약학조성물
HK1022099A (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
HK1018202A (en) Method of treating otitis media with uridine triphosphates and related compounds
MXPA99000011A (en) Method for treating sinusitis with trifosphates deuridine and relative compounds
DE102020125641A1 (de) Wirkstoffe und Arzneimittel für die Therapie von Viruserkrankungen, insbesondere Corona-Infektionen, insbesondere COVID-19

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee